(Total Views: 195)
Posted On: 11/07/2017 7:31:58 PM
Post# of 72446
Article - Could AstraZeneca’s ovarian cancer drug also treat glioblastoma?
"Now researchers in the U.K. say they’ve found a drug that can penetrate that barrier and invade glioblastoma tumors—AstraZeneca’s PARP inhibitor Lynparza (olaparib), which is FDA-approved to treat some patients with ovarian cancer."
https://www.fiercebiotech.com/research/could-...ioblastoma
Kevetrin inhibits PARP by cleaving the enzyme. Here's more from the preclinical study on glioblastoma.
"Results from the Company’s latest in vitro research activities have shown that treatment of glioblastoma cell line (U-87 MG) with Kevetrin™ reactivates p53. The p53 signaling pathway is a crucial regulator of cell cycle and apoptosis. Remarkably, the p53 signaling pathway is defective in most, if not all, human tumors. In U-87 MG, Kevetrin™ activated p53 which induced the expression of p21 that acts as inhibitor of cell cycle progression. Activated p53 also triggered apoptosis by inducing expression of PUMA."
http://www.ipharminc.com/press-release-2/2016...ioblastoma
"Now researchers in the U.K. say they’ve found a drug that can penetrate that barrier and invade glioblastoma tumors—AstraZeneca’s PARP inhibitor Lynparza (olaparib), which is FDA-approved to treat some patients with ovarian cancer."
https://www.fiercebiotech.com/research/could-...ioblastoma
Kevetrin inhibits PARP by cleaving the enzyme. Here's more from the preclinical study on glioblastoma.
"Results from the Company’s latest in vitro research activities have shown that treatment of glioblastoma cell line (U-87 MG) with Kevetrin™ reactivates p53. The p53 signaling pathway is a crucial regulator of cell cycle and apoptosis. Remarkably, the p53 signaling pathway is defective in most, if not all, human tumors. In U-87 MG, Kevetrin™ activated p53 which induced the expression of p21 that acts as inhibitor of cell cycle progression. Activated p53 also triggered apoptosis by inducing expression of PUMA."
http://www.ipharminc.com/press-release-2/2016...ioblastoma
(1)
(0)
